Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs

Natalie Prinzi, Alessandra Raimondi, Marco MacCauro, Massimo Milione, Enrico Garanzini, Martina Torchio, Francesca Corti, Federico Nichetti, Giuseppe Lo Russo, Luca Giacomelli, Vincenzo Mazzaferro, Maria Di Bartolomeo, Ettore Seregni, Filippo De Braud, Sara Pusceddu

Research output: Contribution to journalArticle

Abstract

Aim: Data from 69 well-differentiated gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy + somatostatin analogs (SSAs) after SSA treatment failure were evaluated. Methods: We identified two groups: S1-patients who kept the same SSA treatment beyond progression; S2-patients who switched the SSA with another SSA after progression. Results: Median progression-free survival was 53 and 127 months in S1 and S2, respectively (p = 0.001; hazard ratio: 0.31; 95% CI: 0.15-0.63). Median overall survival was 69 versus 150 months in S1 and S2, respectively (p = 0.004; hazard ratio: 0.32; 95% CI: 0.14-0.71). Conclusion: In patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy plus SSA after SSA failure, the 'switch' strategy of SSA after progression improve progression-free survival and overall survival.

Original languageEnglish
Pages (from-to)3015-3024
Number of pages10
JournalFuture Oncology
Volume15
Issue number26
DOIs
Publication statusPublished - Sep 2019

    Fingerprint

Keywords

  • combinational therapy
  • gasto-entero-pancreatic neuroendocrine tumors
  • peptide receptor radionucleotide therapy
  • somatostatin analogues
  • switching strategy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this